title: Chemotherapy for thymic carcinoma and advanced thymoma in adults.
abstract: BACKGROUND
  Thymic carcinoma or advanced thymoma is a rare cancer of the thymus gland that tends to be aggressive and infiltrate neighbouring organs, making total resection very difficult. Induction or adjuvant chemotherapy, or both, are often used in a multimodality approach to treat people affected by this condition, but the effectiveness of chemotherapy for thymic carcinoma or advanced thymoma remains uncertain.
  
  
  OBJECTIVE
  To assess the role of chemotherapy in adults with thymic carcinoma or advanced thymoma.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 7), MEDLINE (accessed via Ovid from 1966 to July 2012), EMBASE (accessed via Ovid, from 1980 to July 2012), Latin American and Caribbean Literature on Health Sciences (LILACS), the Chinese Biological Medicine Database (CBM, 1978 to July 2012), China National Knowledge Infrastructure (CNKI, 1980 to July 2012) and the Chinese scientific periodical database VIP Information (VIP, 1989 to July 2012). There was no language restriction in searching for studies.
  
  
  METHODS
  We planned to include randomised controlled trials (RCTs) of  trials using chemotherapy (either single-agent or combination chemotherapy plus surgery, radiotherapy or not) for thymic carcinoma and/or advanced thymoma. We planned to include all adults (aged 18 years and over) diagnosed with thymic carcinoma and/or with Masaoka stage III or IV thymic tumours. The intended primary outcomes were overall survival (OS) and progression-free survival (PFS).
  
  
  METHODS
  Two review authors independently evaluated the search results according to the inclusion and exclusion criteria. There were no studies identified for inclusion and therefore no data extraction was completed.
  
  
  RESULTS
  No RCTs were eligible for inclusion in this review. We report details of excluded prospective studies in an additional table and try to provide some useful evidence regarding current practice.
  
  
  CONCLUSIONS
  There were no RCTs eligible for inclusion in this review. In current practice the most common regimen for adult patients with thymic carcinoma or advanced thymoma is cisplatin-based chemotherapy. Considering the condition is rare, it is suggested that an international group is set up to organise and evaluate prospective collection of data from cohorts of patients to inform current clinical practice.
authors: Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.
authors: Mao Ling
authors: ML
authors: Wei
authors: Deying
authors: D
authors: Kang
authors: Lijia
authors: L
authors: Gu
authors: Meng
authors: M
authors: Qiu
authors: Liao
authors: L
authors: Zhengyin
authors: Yanming
authors: Y
authors: Mu
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D011446:Prospective Studies; D013945:Thymoma / Q000188:drug therapy* / Q000473:pathology; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents
references: Thorac Cardiovasc Surg. 2000 Apr;48(2):114-9
references: 11028718
references: Lung Cancer. 2011 Apr;72(1):68-72
references: 20708294
references: J Thorac Cardiovasc Surg. 1994 Feb;107(2):615-20
references: 8302083
references: Jpn J Clin Oncol. 2000 Sep;30(9):385-8
references: 11095135
references: J Thorac Cardiovasc Surg. 2005 Nov;130(5):1413-21
references: 16256797
references: Ann Thorac Surg. 2003 Dec;76(6):1866-72; discussion 1872
references: 14667602
references: Cancer. 1998 Oct 15;83(8):1495-503
references: 9781943
references: Oncology. 2003;65 Suppl 2:44-5
references: 14586146
references: Curr Opin Oncol. 2005 Mar;17(2):140-6
references: 15725919
references: Jpn J Clin Oncol. 2004 Dec;34(12):722-6
references: 15640502
references: Eur J Cardiothorac Surg. 2010 Apr;37(4):819-23
references: 19948412
references: Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):927-33
references: 10705015
references: Lung Cancer. 2004 Jun;44(3):369-79
references: 15140551
references: J Thorac Oncol. 2008 Mar;3(3):265-9
references: 18317069
references: Kyobu Geka. 2005 Jul;58(8 Suppl):739-44
references: 16097629
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: Jpn J Clin Oncol. 2001 Dec;31(12):601-4
references: 11902491
references: J Thorac Cardiovasc Surg. 2009 Jul;138(1):26-31
references: 19577051
references: J Thorac Oncol. 2009 Jan;4(1):119-26
references: 19096319
references: J Thorac Oncol. 2009 Jul;4(7):911-9
references: 19557895
references: Am J Clin Oncol. 2006 Aug;29(4):336-44
references: 16891859
references: Br J Cancer. 2009 Nov 3;101(9):1549-54
references: 19809436
references: Cancer. 1991 Jul 1;68(1):30-3
references: 2049749
references: Eur J Cardiothorac Surg. 2009 Jul;36(1):159-62; discussion 163
references: 19324568
references: Lung Cancer. 2004 Apr;44(1):69-77
references: 15013585
references: Semin Thorac Cardiovasc Surg. 2005 Spring;17(1):41-50
references: 16104360
references: J Clin Oncol. 1990 Aug;8(8):1419-23
references: 2380761
references: Am J Clin Oncol. 2002 Jun;25(3):266-8
references: 12040285
references: Am J Clin Oncol. 2001 Dec;24(6):566-9
references: 11801755
references: Curr Treat Options Oncol. 2008 Dec;9(4-6):277-87
references: 19381821
references: Ann Thorac Surg. 2003 Sep;76(3):878-84; discussion 884-5
references: 12963221
references: Ann Thorac Surg. 2002 Apr;73(4):1076-81
references: 11996244
references: Ann Thorac Surg. 2008 Feb;85(2):365-7
references: 18222226
references: Cancer. 1993 Feb 15;71(4):1219-23
references: 8435796
references: Am J Clin Oncol. 2004 Feb;27(1):68-72
references: 14758136
references: Clin Lung Cancer. 2004 Jul;6(1):28-32
references: 15310414
references: Thorac Surg Clin. 2011 Feb;21(1):107-14, viii
references: 21070992
references: Br J Cancer. 2010 Jun 29;103(1):6-11
references: 20551960
references: J Neurooncol. 2005 Nov;75(2):143-7
references: 16132513
references: Cancer. 2001 Jun 1;91(11):2010-5
references: 11391579
references: J Clin Oncol. 2004 Jan 15;22(2):293-9
references: 14722038
references: Ann Oncol. 2000;11 Suppl 3:245-6
references: 11079148
references: Ann Oncol. 2009 May;20 Suppl 4:147-9
references: 19454438
references: J Thorac Oncol. 2010 Jun;5(6):893-7
references: 20521356
references: J Thorac Oncol. 2006 May;1(4):308-13
references: 17409875
references: Ann Thorac Surg. 2005 Jun;79(6):1840-4
references: 15919267
references: J Clin Oncol. 2004 Apr 15;22(8):1501-9
references: 15084623
references: J Thorac Oncol. 2007 Jan;2(1):73-8
references: 17410014
references: Ann Intern Med. 1998 Jul 15;129(2):100-4
references: 9669967
references: Ann Oncol. 2010 Jun;21(6):1168-1172
references: 19880439
references: Radiother Oncol. 1995 Jan;34(1):9-16
references: 7792406
references: J Clin Oncol. 1996 Mar;14(3):814-20
references: 8622029
references: Am J Med Sci. 2005 Oct;330(4):172-5
references: 16234609
references: Am J Clin Oncol. 1993 Aug;16(4):342-5
references: 8328413
references: Oncol Rep. 2008 Jun;19(6):1525-31
references: 18497960
references: Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):654-64
references: 15183468
references: Cancer. 1981 Dec 1;48(11):2485-92
references: 7296496
references: J Clin Oncol. 1994 Jun;12(6):1164-8
references: 8201378
references: J Thorac Cardiovasc Surg. 1987 May;93(5):708-14
references: 3573783